Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Rev Anticancer Ther. 2012 Jul;12(7):877-9. doi: 10.1586/era.12.71.

New frontiers in therapeutic resistance in cancer.

Author information

1
Falck Division of Medical Oncology, Department of Oncology, Ospedale Niguarda Ca' Granda, Piazza Ospedale Maggiore, 3 20162 Milano, Italy. andrea.sartorebianchi@ospedaleniguarda.it

Abstract

Despite advances in personalized medicine and targeted therapies, therapeutic resistance remains a persistent dilemma encountered by clinicians, scientists and patients. In this article we summarize the highlights of the third Quebec Conference on Therapeutic Resistance in Cancer. This unique meeting provided researchers and clinicians with insights into: intrinsic and acquired resistance; tumor heterogeneity; complexities of biomarker-driven trials; challenges of 'omics data analysis; and models of clinical applications of personalized medicine. Emphasized throughout the conference was the importance of collaborations - between industry and academia, and between basic researchers and clinicians - so that therapeutic resistance can be studied where it matters most, in patients.

PMID:
22845402
DOI:
10.1586/era.12.71
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center